Humanigen Inc. (HGEN) Prices 5M Share Common Offering at $18.50/Sh

Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine storm” with its lead drug candidate lenzilumab™, today announced that it has priced its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $18.50 per share, resulting in gross proceeds to Humanigen of approximately $92.5 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about April 5, 2021. Humanigen also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions.

Jefferies, Credit Suisse and Cantor are acting as joint book-running managers for the offering. Bryan, Garnier & Co. is acting as European lead manager for the offering, Oppenheimer & Co. is acting as lead manager for the offering and H.C. Wainwright & Co., National Securities Corporation and Roth Capital Partners are acting as co-managers for the offering.

Humanigen intends to use the net proceeds from the offering for manufacturing and commercial preparation in the event of receipt of an Emergency Use Authorization from the Food and Drug Administration for lenzilumab™ in hospitalized COVID-19 patients, as well as for working capital and other general corporate purposes.

A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission (the “SEC”). The securities will be offered only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Edgewise sells muscular dystrophy drug to Servier for up to $2.65B
• Safe Pro Group wins U.S. Air Force SBIR contract for FOD AI dataset